Xoma Corp. (XOMA) Receives Outperform Rating from Wedbush
Wedbush restated their outperform rating on shares of Xoma Corp. (NASDAQ:XOMA) in a research note issued to investors on Friday. They currently have a $3.00 price target on the stock, up from their prior price target of $1.42.
Other research analysts also recently issued reports about the company. Cowen and Company restated a neutral rating on shares of Xoma Corp. in a research note on Wednesday, August 10th. Zacks Investment Research downgraded Xoma Corp. from a buy rating to a hold rating in a research note on Friday, August 26th. Finally, Jefferies Group restated a hold rating on shares of Xoma Corp. in a research note on Friday, August 5th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $1.81.
Xoma Corp. (NASDAQ:XOMA) opened at 0.5111 on Friday. The company has a 50 day moving average of $0.60 and a 200 day moving average of $0.68. Xoma Corp. has a 52 week low of $0.44 and a 52 week high of $2.03. The stock has a market capitalization of $61.63 million, a P/E ratio of 46.4636 and a beta of 2.70.
Xoma Corp. (NASDAQ:XOMA) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.01. The business earned $0.40 million during the quarter, compared to analyst estimates of $0.84 million. During the same period last year, the firm earned ($0.20) EPS. Equities analysts expect that Xoma Corp. will post ($0.47) EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Xoma Corp. by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock valued at $2,934,000 after buying an additional 871,594 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Xoma Corp. during the first quarter valued at $374,000. Paloma Partners Management Co bought a new stake in Xoma Corp. during the second quarter valued at $185,000. Bellevue Group AG bought a new stake in Xoma Corp. during the first quarter valued at $174,000. Finally, Spark Investment Management LLC raised its stake in Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares during the last quarter. Institutional investors own 17.13% of the company’s stock.
About Xoma Corp.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.